Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Biochemical markers in persons with preclinical familial Alzheimer disease.

Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL.

Neurology. 2008 Jul 8;71(2):85-92. doi: 10.1212/01.wnl.0000303973.71803.81. Epub 2008 May 28.

PMID:
18509095
2.

Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations.

Ringman JM, Schulman H, Becker C, Jones T, Bai Y, Immermann F, Cole G, Sokolow S, Gylys K, Geschwind DH, Cummings JL, Wan HI.

Arch Neurol. 2012 Jan;69(1):96-104. doi: 10.1001/archneurol.2011.642.

3.

Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease.

Ringman JM, Coppola G, Elashoff D, Rodriguez-Agudelo Y, Medina LD, Gylys K, Cummings JL, Cole GM.

Dement Geriatr Cogn Disord. 2012;33(1):1-5. doi: 10.1159/000335729. Epub 2012 Feb 13.

4.

Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations.

Ringman JM, Fithian AT, Gylys K, Cummings JL, Coppola G, Elashoff D, Pratico D, Moskovitz J, Bitan G.

Dement Geriatr Cogn Disord. 2012;33(4):219-25. doi: 10.1159/000338546. Epub 2012 May 14.

5.

PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.

Balasa M, Vidal-Piñeiro D, Lladó A, Antonell A, Bosch B, Castellanos F, Bargalló N, Bartres-Faz D, Molinuevo JL, Sánchez-Valle R.

J Alzheimers Dis. 2012;30(3):605-16. doi: 10.3233/JAD-2012-111949.

PMID:
22426017
6.

Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.

Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gutierrez Gomez M, Langois CM, Langbaum JB, Roontiva A, Thiyyagura P, Lee W, Ayutyanont N, Lopez L, Moreno S, Muñoz C, Tirado V, Acosta-Baena N, Fagan AM, Giraldo M, Garcia G, Huentelman MJ, Tariot PN, Lopera F, Reiman EM.

JAMA Neurol. 2015 Mar;72(3):316-24. doi: 10.1001/jamaneurol.2014.3314.

7.

Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype.

Ringman JM, Elashoff D, Geschwind DH, Welsh BT, Gylys KH, Lee C, Cummings JL, Cole GM.

Arch Neurol. 2012 Jun;69(6):757-64. doi: 10.1001/archneurol.2012.277.

8.

Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations.

Fortea J, Lladó A, Bosch B, Antonell A, Oliva R, Molinuevo JL, Sánchez-Valle R.

Neurodegener Dis. 2011;8(4):202-7. doi: 10.1159/000322229. Epub 2011 Jan 5.

PMID:
21212633
9.

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM.

Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.

PMID:
17210801
10.

Increased prevalence of significant recurrent headache in preclinical familial Alzheimer's disease mutation carriers.

Ringman JM, Romano JD, Medina LD, Rodriguez-Agudelo Y, Schaffer B, Varpetian A, Ortiz F, Fitten LJ, Cummings JL, Baloh RW.

Dement Geriatr Cogn Disord. 2008;25(4):380-4. doi: 10.1159/000121986. Epub 2008 Mar 29.

PMID:
18376127
11.

Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.

Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ.

Neurobiol Aging. 2009 May;30(5):682-90. Epub 2007 Sep 24.

12.

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.

Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TL, Stoops EE, Vanderstichele HM, Brix B, Darby HD, Vandijck ML, Ladenson JH, Morris JC, Holtzman DM, Fagan AM.

JAMA Neurol. 2015 Sep;72(9):1029-42. doi: 10.1001/jamaneurol.2015.1285.

13.

Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.

Thordardottir S, Ståhlbom AK, Ferreira D, Almkvist O, Westman E, Zetterberg H, Eriksdotter M, Blennow K, Graff C.

J Alzheimers Dis. 2015;43(4):1393-402. doi: 10.3233/JAD-140339.

PMID:
25182737
14.

Detecting Alzheimer disease before it happens: The key to prevention?

Quinn J, Sabbagh MN.

Neurology. 2008 Jul 8;71(2):78-9. doi: 10.1212/01.wnl.0000316808.21277.69. No abstract available.

PMID:
18606962
15.

Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.

Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM.

Arch Neurol. 2009 May;66(5):638-45. doi: 10.1001/archneurol.2009.55.

16.

Dementia mimicking Alzheimer's disease Owing to a tau mutation: CSF and PET findings.

Tolboom N, Koedam EL, Schott JM, Yaqub M, Blankenstein MA, Barkhof F, Pijnenburg YA, Lammertsma AA, Scheltens P, van Berckel BN.

Alzheimer Dis Assoc Disord. 2010 Jul-Sep;24(3):303-7. doi: 10.1097/WAD.0b013e3181cf35ec.

PMID:
20683187
17.

Relative ratio and level of amyloid-β 42 surrogate in cerebrospinal fluid of familial Alzheimer disease patients with presenilin 1 mutations.

Tagami S, Okochi M, Yanagida K, Kodama T, Arai T, Kuwano R, Ikeuchi T, Takeda M.

Neurodegener Dis. 2014;13(2-3):166-70. doi: 10.1159/000355258. Epub 2013 Oct 30.

PMID:
24192669
18.

Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.

Schöll M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Långström B, Almkvist O, Graff C, Nordberg A.

Neurology. 2012 Jul 17;79(3):229-36. doi: 10.1212/WNL.0b013e31825fdf18. Epub 2012 Jun 13.

PMID:
22700814
19.

Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.

Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, Fagan AM, Shah AR, Alvarez S, Arbelaez A, Giraldo M, Acosta-Baena N, Sperling RA, Dickerson B, Stern CE, Tirado V, Munoz C, Reiman RA, Huentelman MJ, Alexander GE, Langbaum JB, Kosik KS, Tariot PN, Lopera F.

Lancet Neurol. 2012 Dec;11(12):1048-56. doi: 10.1016/S1474-4422(12)70228-4. Epub 2012 Nov 6.

20.

Formation of tau inclusions in knock-in mice with familial Alzheimer disease (FAD) mutation of presenilin 1 (PS1).

Tanemura K, Chui DH, Fukuda T, Murayama M, Park JM, Akagi T, Tatebayashi Y, Miyasaka T, Kimura T, Hashikawa T, Nakano Y, Kudo T, Takeda M, Takashima A.

J Biol Chem. 2006 Feb 24;281(8):5037-41. Epub 2005 Dec 23.

Items per page

Supplemental Content

Write to the Help Desk